In Vitro Monitoring of Dissolution of an Immediate Release Tablet by Focused Beam Reflectance Measurement

Changes in in vitro drug release profiles of oral dosage forms are commonly observed due to storage of drug product at elevated temperature and humidity. An example is presented of an immediate release drug product which underwent changes to both release profile and crystal form on storage at elevat...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 7; no. 5; pp. 1508 - 1515
Main Authors Coutant, Carrie A, Skibic, Michael J, Doddridge, Greg D, Kemp, Craig A, Sperry, David C
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 04.10.2010
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Changes in in vitro drug release profiles of oral dosage forms are commonly observed due to storage of drug product at elevated temperature and humidity. An example is presented of an immediate release drug product which underwent changes to both release profile and crystal form on storage at elevated humidity. The dissolution rate for unstressed tablets was comparable regardless of the crystal form present. Decreased release rate was only observed for stressed tablets that exhibited crystal form conversion. The cause of the dissolution change was determined by evaluating tablets manufactured with three drug substance crystal forms by fiber optic ultraviolet detection and focused beam reflectance measurement (FBRM). Tablets were also analyzed by near-infrared spectroscopy for crystal form determination. The observed change in dissolution rate correlated with detection of a greater number of larger particles by FBRM. FBRM results indicate increased aggregation of the tablet material due to crystal form conversion, resulting in the presence of slowly disintegrating and dissolving granules during the dissolution process. The improved understanding of the dissolution process allows evaluation of the potential in vivo impact of the stability changes.
AbstractList Changes in in vitro drug release profiles of oral dosage forms are commonly observed due to storage of drug product at elevated temperature and humidity. An example is presented of an immediate release drug product which underwent changes to both release profile and crystal form on storage at elevated humidity. The dissolution rate for unstressed tablets was comparable regardless of the crystal form present. Decreased release rate was only observed for stressed tablets that exhibited crystal form conversion. The cause of the dissolution change was determined by evaluating tablets manufactured with three drug substance crystal forms by fiber optic ultraviolet detection and focused beam reflectance measurement (FBRM). Tablets were also analyzed by near-infrared spectroscopy for crystal form determination. The observed change in dissolution rate correlated with detection of a greater number of larger particles by FBRM. FBRM results indicate increased aggregation of the tablet material due to crystal form conversion, resulting in the presence of slowly disintegrating and dissolving granules during the dissolution process. The improved understanding of the dissolution process allows evaluation of the potential in vivo impact of the stability changes.Changes in in vitro drug release profiles of oral dosage forms are commonly observed due to storage of drug product at elevated temperature and humidity. An example is presented of an immediate release drug product which underwent changes to both release profile and crystal form on storage at elevated humidity. The dissolution rate for unstressed tablets was comparable regardless of the crystal form present. Decreased release rate was only observed for stressed tablets that exhibited crystal form conversion. The cause of the dissolution change was determined by evaluating tablets manufactured with three drug substance crystal forms by fiber optic ultraviolet detection and focused beam reflectance measurement (FBRM). Tablets were also analyzed by near-infrared spectroscopy for crystal form determination. The observed change in dissolution rate correlated with detection of a greater number of larger particles by FBRM. FBRM results indicate increased aggregation of the tablet material due to crystal form conversion, resulting in the presence of slowly disintegrating and dissolving granules during the dissolution process. The improved understanding of the dissolution process allows evaluation of the potential in vivo impact of the stability changes.
Changes in in vitro drug release profiles of oral dosage forms are commonly observed due to storage of drug product at elevated temperature and humidity. An example is presented of an immediate release drug product which underwent changes to both release profile and crystal form on storage at elevated humidity. The dissolution rate for unstressed tablets was comparable regardless of the crystal form present. Decreased release rate was only observed for stressed tablets that exhibited crystal form conversion. The cause of the dissolution change was determined by evaluating tablets manufactured with three drug substance crystal forms by fiber optic ultraviolet detection and focused beam reflectance measurement (FBRM). Tablets were also analyzed by near-infrared spectroscopy for crystal form determination. The observed change in dissolution rate correlated with detection of a greater number of larger particles by FBRM. FBRM results indicate increased aggregation of the tablet material due to crystal form conversion, resulting in the presence of slowly disintegrating and dissolving granules during the dissolution process. The improved understanding of the dissolution process allows evaluation of the potential in vivo impact of the stability changes.
Author Doddridge, Greg D
Coutant, Carrie A
Skibic, Michael J
Kemp, Craig A
Sperry, David C
Author_xml – sequence: 1
  givenname: Carrie A
  surname: Coutant
  fullname: Coutant, Carrie A
  email: cacoutant@lilly.com
– sequence: 2
  givenname: Michael J
  surname: Skibic
  fullname: Skibic, Michael J
– sequence: 3
  givenname: Greg D
  surname: Doddridge
  fullname: Doddridge, Greg D
– sequence: 4
  givenname: Craig A
  surname: Kemp
  fullname: Kemp, Craig A
– sequence: 5
  givenname: David C
  surname: Sperry
  fullname: Sperry, David C
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20715796$$D View this record in MEDLINE/PubMed
BookMark eNptkE1LAzEQhoMo1q-Df0ByEfRQzcdmP45arRYUQarXZTadlchuUpPswX9vSmsP4mlmeJ8ZmOeQ7FpnkZBTzq44E_y6X3LGeFbkO-SAq0yOS1mJ3W1fZiNyGMInYyJTQu6TkWAFV0WVHxAzs_TdRO_os7MmOm_sB3UtvTMhuG6IxtnVCJbO-h4XBiLSV-wQAtI5NB1G2nzTqdNDwAW9RehT3HaoI1iN9DmBg8cebTwmey10AU829Yi8Te_nk8fx08vDbHLzNAbJVRxzCQx12fBKKaFQiBZYg7xNX2gtpVg0JcOs0ipLednAoi1kWWZYglJ5CuQRuVjfXXr3NWCIdW-Cxq4Di24INReF5DnjVZ7Qsw06NOm5eulND_67_tWTgMs1oL0LwWO7RTirV-rrrfrEXv9htYmwEhg9mO7fjfP1BuhQf7rB2-TlH-4Hc8yQOQ
CitedBy_id crossref_primary_10_1111_jphp_12271
crossref_primary_10_3390_pharmaceutics14010208
crossref_primary_10_1016_j_ces_2013_07_013
crossref_primary_10_1016_j_jddst_2023_104891
crossref_primary_10_1007_s11095_011_0535_1
crossref_primary_10_3109_03639045_2014_947508
crossref_primary_10_1016_j_xphs_2020_05_019
crossref_primary_10_1016_j_ijpharm_2024_124778
crossref_primary_10_1016_j_heliyon_2024_e26025
crossref_primary_10_1016_j_susmat_2025_e01341
crossref_primary_10_1080_10837450_2018_1559189
crossref_primary_10_1007_s11095_017_2129_z
crossref_primary_10_2174_1573412915666181210144338
crossref_primary_10_1021_acs_cgd_3c01147
crossref_primary_10_1016_j_ijpharm_2020_119838
crossref_primary_10_1002_cjce_23465
Cites_doi 10.1007/s11095-008-9822-x
10.1023/A:1018917729477
10.1016/0731-7085(87)80024-9
10.1002/jps.20818
10.1016/j.ijpharm.2004.08.003
10.1016/j.ces.2008.09.007
10.1201/b14198-3
10.1016/j.ijpharm.2008.08.010
10.1016/S0928-0987(01)00095-1
10.1080/03639040701384918
10.1016/0378-5173(93)90132-Y
10.1016/j.ijpharm.2008.10.010
10.1016/j.ejps.2009.01.008
10.1016/S0378-5173(00)00530-5
10.1021/op049783p
10.1023/A:1018951309506
10.1002/jps.21899
10.1002/jps.10337
10.1021/cg800934h
10.1002/crat.200900402
10.1021/ie800839s
ContentType Journal Article
Copyright Copyright © 2010 American Chemical Society
Copyright_xml – notice: Copyright © 2010 American Chemical Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1021/mp1001476
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Monitoring of Dissolution of an Immediate Release Tablet
EISSN 1543-8392
EndPage 1515
ExternalDocumentID 20715796
10_1021_mp1001476
c411198773
Genre Journal Article
GroupedDBID -
123
4.4
53G
55A
5VS
7~N
AABXI
ABMVS
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
DU5
EBS
ED
ED~
EJD
F5P
GNL
H~9
IH9
JG
JG~
LG6
P2P
RNS
ROL
UI2
VF5
VG9
W1F
X
---
-~X
AAYXX
ABBLG
ABJNI
ABLBI
ABQRX
ADHLV
AHGAQ
CITATION
CUPRZ
GGK
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-a315t-13a0ec8b195525e22fa0be1f384cc332db80e49c545528badf73884e8a556e493
IEDL.DBID ACS
ISSN 1543-8384
1543-8392
IngestDate Fri Jul 11 09:42:59 EDT 2025
Thu Jan 02 22:36:27 EST 2025
Tue Jul 01 04:33:29 EDT 2025
Thu Apr 24 22:56:45 EDT 2025
Thu Aug 27 13:42:50 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords near-infrared spectroscopy
Tablet dissolution
focused beam reflectance measurement
crystal form
dissolution mechanism
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a315t-13a0ec8b195525e22fa0be1f384cc332db80e49c545528badf73884e8a556e493
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 20715796
PQID 1273160196
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_1273160196
pubmed_primary_20715796
crossref_primary_10_1021_mp1001476
crossref_citationtrail_10_1021_mp1001476
acs_journals_10_1021_mp1001476
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
VG9
W1F
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
BAANH
AQSVZ
ED~
UI2
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-10-04
PublicationDateYYYYMMDD 2010-10-04
PublicationDate_xml – month: 10
  year: 2010
  text: 2010-10-04
  day: 04
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmaceutics
PublicationTitleAlternate Mol. Pharmaceutics
PublicationYear 2010
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References Hersen-Delesalle C. (ref3/cit3) 2007; 33
Costa P. (ref5/cit5) 2001; 13
Han J.-H. (ref14/cit14) 2009; 11
Banakar U. V. (ref7/cit7) 1991; 49
Kamada K. (ref19/cit19) 2009; 368
Barrett P. (ref10/cit10) 2005; 9
Baxter J. L. (ref23/cit23) 2005; 292
ref21/cit21
Patel A. D. (ref20/cit20) 2000; 206
Brits M. (ref8/cit8) 2010; 99
Sarkar D. (ref13/cit13) 2009; 64
Lu A. T. K. (ref6/cit6) 1993; 10
Tajarobi F. (ref16/cit16) 2009; 37
Late S. G. (ref9/cit9) 2009; 365
Rohrs B. R. (ref4/cit4) 1999; 16
Lindenberg C. (ref12/cit12) 2009; 9
Bai G. (ref22/cit22) 2007; 96
Sun Y. Z. (ref15/cit15) 2009; 44
Blanco M. (ref17/cit17) 2003; 92
Gordon M. S. (ref2/cit2) 1993; 97
Kail N. (ref11/cit11) 2009; 48
Gimet R. (ref18/cit18) 1987; 5
Gray V. (ref1/cit1) 2009; 26
References_xml – volume: 26
  start-page: 1289
  year: 2009
  ident: ref1/cit1
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-008-9822-x
– volume: 10
  start-page: 1308
  year: 1993
  ident: ref6/cit6
  publication-title: Pharm. Res.
  doi: 10.1023/A:1018917729477
– volume: 5
  start-page: 205
  year: 1987
  ident: ref18/cit18
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/0731-7085(87)80024-9
– volume: 96
  start-page: 2327
  year: 2007
  ident: ref22/cit22
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.20818
– volume: 292
  start-page: 17
  year: 2005
  ident: ref23/cit23
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2004.08.003
– volume: 64
  start-page: 9
  year: 2009
  ident: ref13/cit13
  publication-title: Chem. Eng. Sci.
  doi: 10.1016/j.ces.2008.09.007
– ident: ref21/cit21
– volume: 11
  issue: 2
  year: 2009
  ident: ref14/cit14
  publication-title: AAPS J.
– volume: 49
  start-page: 19
  volume-title: Pharmaceutical dissolution testing
  year: 1991
  ident: ref7/cit7
  doi: 10.1201/b14198-3
– volume: 365
  start-page: 4
  year: 2009
  ident: ref9/cit9
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2008.08.010
– volume: 13
  start-page: 123
  year: 2001
  ident: ref5/cit5
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/S0928-0987(01)00095-1
– volume: 33
  start-page: 1297
  year: 2007
  ident: ref3/cit3
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.1080/03639040701384918
– volume: 97
  start-page: 119
  year: 1993
  ident: ref2/cit2
  publication-title: Int. J. Pharm.
  doi: 10.1016/0378-5173(93)90132-Y
– volume: 368
  start-page: 103
  year: 2009
  ident: ref19/cit19
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2008.10.010
– volume: 37
  start-page: 89
  year: 2009
  ident: ref16/cit16
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2009.01.008
– volume: 206
  start-page: 63
  year: 2000
  ident: ref20/cit20
  publication-title: Int. J. Pharm.
  doi: 10.1016/S0378-5173(00)00530-5
– volume: 9
  start-page: 348
  year: 2005
  ident: ref10/cit10
  publication-title: Org. Process Res. Dev.
  doi: 10.1021/op049783p
– volume: 16
  start-page: 1850
  year: 1999
  ident: ref4/cit4
  publication-title: Pharm. Res.
  doi: 10.1023/A:1018951309506
– volume: 99
  start-page: 1138
  year: 2010
  ident: ref8/cit8
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.21899
– volume: 92
  start-page: 823
  year: 2003
  ident: ref17/cit17
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.10337
– volume: 9
  start-page: 1124
  year: 2009
  ident: ref12/cit12
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg800934h
– volume: 44
  start-page: 1223
  year: 2009
  ident: ref15/cit15
  publication-title: Cryst. Res. Technol.
  doi: 10.1002/crat.200900402
– volume: 48
  start-page: 2936
  year: 2009
  ident: ref11/cit11
  publication-title: Ind. Eng. Chem. Res.
  doi: 10.1021/ie800839s
SSID ssj0024523
Score 2.0491362
Snippet Changes in in vitro drug release profiles of oral dosage forms are commonly observed due to storage of drug product at elevated temperature and humidity. An...
SourceID proquest
pubmed
crossref
acs
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1508
SubjectTerms Administration, Oral
Biological Availability
Chemistry, Pharmaceutical - methods
Crystallization
Humans
Models, Biological
Solubility
Spectroscopy, Near-Infrared - methods
Tablets - administration & dosage
Tablets - chemistry
Tablets - pharmacokinetics
Tablets, Enteric-Coated - administration & dosage
Tablets, Enteric-Coated - chemistry
Tablets, Enteric-Coated - pharmacokinetics
Title In Vitro Monitoring of Dissolution of an Immediate Release Tablet by Focused Beam Reflectance Measurement
URI http://dx.doi.org/10.1021/mp1001476
https://www.ncbi.nlm.nih.gov/pubmed/20715796
https://www.proquest.com/docview/1273160196
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LT9wwEB5RuPRCW1rotoDMQ4gDoRvHTpwjBVZQCYRgQdwi27GlFWyC2Oxh-fXMJPtoxaPHxHZiecaZL56ZbwC2uQpj1451kIvcBwSpg9SFPlAC7wodEacYRVucxyfX4s-tvJ2DrTc8-Dz81X8gmiCRxB9ggccqoT-sg8OrGaGerGu4IRSIAhUpMaEP-nsomR47-Nf0vIEna7vS-QRHk-ycJpzkbn9YmX379JKs8b0pf4bFMa5kB40ifIE5VyzBzkVDTD3aY91ZntVgj-2wixll9egr9E4LdtOrHkvW7HE67GOlZ0e9qW7SpS7Yab_ONakcu0SDhSaQdSn5qmJmxDqlHQ5czn473cdmTx4BUip2NjuI_AbXnePu4UkwLsIQoKAklarXbWeVCVMpuXSce902KE1caWujiOdGtZ1ILSIxyZXRuU8ihZJWWsoYG6JlmC_Kwn0HlnrnEmcSiyMF99IInyfK4CclVSEOasE6Sikbb6JBVvvHeZhNl7MFuxMBZnZMYU6VNO5f67o57frQ8Ha81mljogUZ7ipylejClUN8NaeKXsQd1IKVRj2mj-GIyiiD98f_pvsTPtaxBhRuIFZhvnocujWEMJVZr1X4Gei_6Fw
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKOcCFN-0CLW6FKg5Nu3HsxDn2wWq3L1WwRb1FtmNLK9ikarKH5dcz42Q3LSqCYxLbGXnGmS_2zDeEfGIyjG0_VkHOcxcgpA5SG7pAcrjLVYScYhhtcREPr_jJtbhuaXIwFwaEqGCkyh_id-wC4f70BtmCeBI_Io8BhDD80To4-tbx6glfyg0QQRTISPIFi9DdruiBTHXfA_0FVnr3Mnje1Cnygvmokh97s1rvmV9_cDb-n-QvyLMWZdKDxixekhVbvCI7lw1N9XyXjrusq2qX7tDLjsB6_ppMRgX9PqlvS9qseNz6o6Wjx5OlpeKlKuho6jNPaku_gvsCh0jHmIpVUz2ng9LMKpvTQ6um8Njh-QCaGD3vtiXfkKvBl_HRMGhLMgSgNoGF61XfGqnDVAgmLGNO9TXoFibcmChiuZZ9y1MDuEwwqVXukkiC3qUSIoYH0VuyWpSFXSc0ddYmVicGenLmhOYuT6SGD0wqQ-jUI5swm1m7pKrMn5azMFtOZ498XugxMy2hOdbV-PlQ0-1l05uGxeOhRlsLY8hgjeHBiSpsOYNXM6zvhUxCPbLWWMlyGAYYDfN53_1L3I_kyXB8fpadjS5O35OnPgoBAxH4B7Ja387sBoCbWm96q_4NdgjwvQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB5BkRAX3o_lUQxCFYembBw7cY6lZdXlUVawrXqLbMeWVu0mqyZ7WH49M0k2C6gIjokfGXnGmbFn5huAN1yFsRvGOshF7gMyqYPUhT5QAt8KHRGmGEVbHMdHJ-LjmTzrDoqUC4NEVDhT1TjxaVcvct8hDITv5gtCDBJJfB1ukLuODlv7B9832HqyKeeGVkEUqEiJNZLQr0NJC9nqdy30F9OyUTGjO_C1J66JLDnfW9Zmz_74A7fx_6m_C7c7a5Ptt-JxD6654j7sTFq46tUum26yr6pdtsMmGyDr1QOYjQt2OqsvS9bufLoCZKVnh7NeYulRF2w8bzJQase-oRpDxcimlJJVM7Nio9IuK5ez907PsdmTn4BEjX3ZXE8-hJPRh-nBUdCVZgiQfZIK2Ouhs8qEqZRcOs69HhrkMS66tVHEc6OGTqQW7TPJldG5TyKF_FdayhgbokewVZSFewIs9c4lziQWRwrupRE-T5TBH02qQhw0gG1c0azbWlXWeM15mPXLOYC3a15mtgM2p_oaF1d1fd13XbRoHld1erUWiAz3GjlQdOHKJX6aU50vQhQawONWUvppONpqlNf79F_kvoSbk8NR9nl8_OkZ3GqCESgeQTyHrfpy6V6gjVOb7UawfwJm0PNA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+vitro+monitoring+of+dissolution+of+an+immediate+release+tablet+by+focused+beam+reflectance+measurement&rft.jtitle=Molecular+pharmaceutics&rft.au=Coutant%2C+Carrie+A&rft.au=Skibic%2C+Michael+J&rft.au=Doddridge%2C+Greg+D&rft.au=Kemp%2C+Craig+A&rft.date=2010-10-04&rft.eissn=1543-8392&rft.volume=7&rft.issue=5&rft.spage=1508&rft_id=info:doi/10.1021%2Fmp1001476&rft_id=info%3Apmid%2F20715796&rft.externalDocID=20715796
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon